Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).

NCT02327754 is registered in ClinicalTrials.gov with Sanwa Kagaku Kenkyusho Co., Ltd. as lead sponsor.

NCT NCT02327754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02327754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).
Lead sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
December 31, 2016
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy